PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.76%
Revenue growth at 50-75% of RUN's 9.37%. Martin Whitman would worry about competitiveness or product relevance.
-2.26%
Negative gross profit growth while RUN is at 27.04%. Joel Greenblatt would examine cost competitiveness or demand decline.
-171.19%
Negative EBIT growth while RUN is at 2.71%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
27.21%
Operating income growth above 1.5x RUN's 2.71%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
-212.19%
Negative net income growth while RUN stands at 158.50%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-213.95%
Negative EPS growth while RUN is at 160.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-225.64%
Negative diluted EPS growth while RUN is at 155.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.14%
Share reduction more than 1.5x RUN's 0.84%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
-11.05%
Reduced diluted shares while RUN is at 4.23%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-207.64%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-221.36%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-73.93%
Negative 10Y revenue/share CAGR while RUN stands at 200.93%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-64.53%
Negative 5Y CAGR while RUN stands at 95.16%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-38.36%
Negative 3Y CAGR while RUN stands at 15.43%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-162.53%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
85.23%
Positive OCF/share growth while RUN is negative. John Neff might see a comparative advantage in operational cash viability.
88.04%
Positive 3Y OCF/share CAGR while RUN is negative. John Neff might see a big short-term edge in operational efficiency.
87.07%
Net income/share CAGR at 50-75% of RUN's 161.00%. Martin Whitman might question if the firm’s product or cost base lags behind.
-66.36%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
23.38%
Below 50% of RUN's 549.27%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-82.27%
Negative equity/share CAGR over 10 years while RUN stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-77.05%
Negative 5Y equity/share growth while RUN is at 391.51%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
633.78%
3Y equity/share CAGR above 1.5x RUN's 247.09%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.90%
AR growth is negative/stable vs. RUN's 9.12%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
2.37%
Inventory shrinking or stable vs. RUN's 30.20%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-7.62%
Negative asset growth while RUN invests at 4.28%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-17.46%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-3.83%
We’re deleveraging while RUN stands at 8.64%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-36.77%
Our R&D shrinks while RUN invests at 8.78%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-9.80%
We cut SG&A while RUN invests at 7.34%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.